Magnesium sulfate in prevention of vancomycin+piperacillin-tazobactam nephrotoxicity

Evaluation of magnesium sulfate efficacy in prevention of acute kidney injury induced by vancomycin+piperacillin-tazobactam combination

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20100228003449N26

Enrollment

Registered

2019-10-20

Start date

2019-09-23

Completion date

Unknown

Last updated

2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury. Acute renal failure with tubular necrosis

Interventions

Intervention 1: Magnesium group: This patients will receive vancomycin (15mg/kg every 8-12 hours) + piperacillin-tazobactam (4.5 g every 6 hour) concomitant with intravenous magnesium sulfate on the b

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients with age between 18-75 years Patients without history of renal failure Patients with indication to receive vancomycin+piperacillin-tazobactam

Exclusion criteria

Exclusion criteria: known history of hypersensitivity reactions to vancomycin and betalactams Pregnancy Patients with creatinine clearance less than 60 ml/min

Design outcomes

Primary

Measure	Time frame
Incidence of acute kidney injury. Timepoint: Daily. Method of measurement: Increase in serum creatinine by 0.3 mg/dl or more than 50% from the baseline value.;Time of acute kidney injury occurrence. Timepoint: Daily. Method of measurement: Recording of incidence time.	—

Secondary

Measure	Time frame
Length of ICU stay. Timepoint: Daily. Method of measurement: Recording of stay days.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Khalili

Tehran University of Medical Sciences

khalilih@tums.ac.ir+98 21 6658 1598

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026